Comet Therapeutics of Cambridge, MA, revealed a $28.5m series A round on 19 June to develop a broad portfolio of drug candidates based on its ability to reengineer Coenzyme A (CoA)-related metabolism for the treatment of metabolic disorders, neuro-metabolic diseases, immuno-metabolic conditions and other life-threatening diseases. Canaan Partners and prior investor Sofinnova Partners co-led the round with participation from existing backer INKEF Capital and new investor BioInnovation Capital. Comet president and CEO David de Graaf previously was president and CEO of Syntimmune Inc., which was purchased by Alexion Pharmaceuticals Inc. for $400m in 2018. (Also see "Alexion Continues Pipeline Rebuilding With $400m Takeout Of Syntimmune" - Scrip, 26 September, 2018.) The company said its CoMET Platform "enables precise targeting of specific CoA species to diseased tissues and organelles within cells where these species are depleted, thereby restoring normal cellular metabolism and regulation that underlie basic human health."

Finance Watch: Polaris Piles On As Multiple Life Science VCs Raise New Funds

More from Financing

More from Business